Clinical

Dataset Information

0

Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer


ABSTRACT: This trial is being performed in two parts: Dose Escalation and Dose Expansion. The primary objective for the Dose Escalation part is to determine the safety and tolerability at different doses of DS-8273a administered in combination with nivolumab and to identify the dose combination for the Dose Expansion cohort in subjects with mismatch repair (MMR)-proficient advanced colorectal cancer. The primary objectives for the Dose Expansion part are: * To further evaluate the safety and tolerability of DS-8273a administered at the selected dose in combination with nivolumab in subjects with MMR-proficient advanced colorectal cancer * To evaluate preliminary anti-tumor activity of DS-8273a plus nivolumab administered at the selected dose in subjects with MMR-proficient advanced colorectal cancer

DISEASE(S): Colorectal Neoplasm,Colorectal Neoplasms

PROVIDER: 2231940 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2365595 | ecrin-mdr-crc
| 2399809 | ecrin-mdr-crc
2012-06-01 | E-GEOD-38405 | biostudies-arrayexpress
2014-12-31 | GSE55930 | GEO
2022-01-01 | E-MTAB-4030 | biostudies-arrayexpress
| 2181052 | ecrin-mdr-crc
2014-07-14 | GSE46036 | GEO
| 2107519 | ecrin-mdr-crc
2007-03-16 | GSE7274 | GEO
| 2308164 | ecrin-mdr-crc